期刊文献+

利奈唑胺在高龄患者中的疗效与安全性分析

下载PDF
导出
摘要 目的评价利奈唑胺在高龄(≥80岁)革兰阳性球菌感染人群中的治疗疗效与安全性。方法回顾性分析2007年7月~2011年7月沈阳军区总医院干部病房一科高龄革兰阳性球菌感染患者应用利奈唑胺治疗情况。结果 14例高龄革兰阳性球菌感染患者接受利奈唑胺治疗,均为男性,年龄80~97岁,平均(88.5±4.9)岁,存在多种基础疾病,治疗时间5~15d,平均(10±4.7)d,其中2例死亡,8例(57.1%)有效,10例(71.4%)出现不良反应,以血小板减少最常见,其次是心功能恶化,能耐受利奈唑胺治疗者均治疗有效。结论利奈唑胺在高龄人群中应用时,不良反应有所增加,应严格监测血小板水平和心功能变化。患者如能耐受,利奈唑胺仍有很好的疗效。
出处 《中华保健医学杂志》 2013年第3期256-257,263,共3页 Chinese Journal of Health Care and Medicine
  • 相关文献

参考文献18

  • 1Li Z,Willke RJ,Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or van- comycin:a randomized,muhicenter trial[J]. Pharmacotherapy,2001, 21:263-274.
  • 2Raad I,Haehem R,Hanna H, et al. Prospective,randomized study eomparing quinupristin-dalfopristin with linezolid in the treatment of vaneomyein-resistant Enterococeus faecium inffeetions[J]. J An- timicrob Chemother, 2004,53 : 646-649.
  • 3Shinabarger DL,Marotti KR, Murray RW,et al. Mechanism of ac- tion of oxazolidinenes:effects of linezolid and eperezolid on trans- lation reactions [ J ]. Antimicrob Agents Chemother, 1997,41 : 2132- 2136.
  • 4Stalker DJ,Jungbluth GL,Hopkins NK,et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous line- zolid,an oxazolidinone antibiotic,in healthy volunteers [J]. J An- timicrob Chemother, 2003,51 : 1239-1246.
  • 5Rubinstein E,Isturiz R,Standiford HC,et al. Worldwide assess- ment of linezolid's clinical safety and tolerability:comparator- controlled phase Ⅲ studies[J]. Antimicrob Agents Chemother, 2003,47: 1824-1831.
  • 6Nasraway SA,Shorr AF,Kuter D J, Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use[J]. Clin In- fect Dis, 2003,37 : 1609-1616.
  • 7林东昉,吴菊芳,张婴元,郑经川,缪竞智,郑丽叶,盛瑞媛,周新,沈华浩,吴卫红,周乐,汪复.利奈唑胺与万古霉素治疗革兰阳性菌感染的随机、双盲、对照、多中心临床试验[J].中国感染与化疗杂志,2009,9(1):10-17. 被引量:56
  • 8Wu VC,Wang YT,Wang CY,et al. High frequency of linezolid- associated thrombocytopenia and anemia among patients with end-stage renal disease[J]. Clin Infect Dis,2006,42: 66-72.
  • 9Grau S, Morales-Molina JA,Mateu -de AJ, et al. Linezolid : low pre-treatment platelet values could increase the risk of thrombo- cytopenia[J]. J Antimicrob Chemother, 2005,56 : 440-441.
  • 10De Antonio JM,Grau S,Morales-Molina JA,et a. Thrombocy- topenia and anemia associated with linezolid in patients with kidney failure[J].Clin Infect Dis,2006,42:1500-1501.

二级参考文献40

  • 1周颖杰.利奈唑胺治疗严重感染建议在治疗复杂患者时监测不良反应[J].中国感染与化疗杂志,2006,6(5):345-345. 被引量:17
  • 2朱德妹,汪复,张婴元.2005年上海地区细菌耐药性监测[J].中国感染与化疗杂志,2006,6(6):371-376. 被引量:82
  • 3Niwa T, Suzuki A, Sakakibara S,et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy[J]. Clin Ther, 2009, 31 (10) : 2126-2133.
  • 4Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression[J]. JAMA,2001,285(10) : 1291.
  • 5Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteriemia [J]. Clin Infect Dis, 2008, 46(2):193-200.
  • 6Maclayton DO, Suda KJ, Coval KA, et al. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and out comes in inpatients undergoing hemodialysis[J]. Clin Ther 2006,28(8) : 1208-1216.
  • 7Soriano A, Ortega M, Garcia S,et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid[J]. Antimicrob Agents Chemother, 2007, 51(7) :2559-2563.
  • 8Vanderschueren S, DeWeerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care [J]. Crit Care Med,2000,28(6):1871-1876.
  • 9Strauss R, Wehler M, Mehler K,et al. Thrombocytopenia in patients in the medical intensive care unit: bleeding preva lence, transfusion requirements, and outcome[J]. Crit Care Med, 2002,30(8) : 1765-1771.
  • 10Nasraway SA, Shorr AF, Kuter DJ,et al. Linezolid does not increase the risk of thromboeytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use[J]. Clin Infect Dis, 2003, 37(12) : 1609-1616.

共引文献120

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部